RPG Life Sciences Ltd has agreed to acquire Actis Generics, a move designed to bolster its position in the active pharmaceutical ingredients (API) market.
The transaction is part of a broader restructuring effort that also involves transferring the company's existing API assets to a separate entity, RPG Active Pharma.
This dual approach allows the firm to streamline its operations while simultaneously expanding its product portfolio through the acquisition.
The strategic shift signals a clear focus on vertical integration within the pharmaceutical supply chain.
By consolidating its API capabilities under a dedicated subsidiary and adding new capacity via the Actis Generics deal, RPG Life Sciences aims to secure a more robust upstream position.
This is particularly relevant for generic drug manufacturers seeking to mitigate supply chain vulnerabilities and control input costs.